Table 4. Univariate and multivariate analyses of specific organ sites metastasis-free survival in patients of resected lung adenocarcinoma.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| Contralateral lung metastasis-free survival | ||||||
| Age* | 0.999 | 0.974 to 1.025 | 0.938 | 1.002 | 0.973 to 1.032 | 0.904 |
| Female | 1.314 | 0.743 to 2.324 | 0.348 | 1.337 | 0.728 to 2.455 | 0.349 |
| Tumor size† | 1.678 | 1.443 to 1.950 | < 0.001 | 1.293 | 1.061 to 1.576 | 0.011 |
| N2 (vs. N0 or N1) | 5.110 | 2.828 to 9.234 | < 0.001 | 1.373 | 0.634 to 2.972 | 0.421 |
| Stage II or III (vs. stage I) | 6.228 | 3.481 to 11.145 | < 0.001 | 2.123 | 0.906 to 4.976 | 0.083 |
| Visceral pleural invasion | 2.053 | 1.068 to 3.948 | 0.031 | 0.991 | 0.475 to 2.067 | 0.981 |
| Angiolymphatic invasion | 4.089 | 2.313 to 7.228 | < 0.001 | 1.796 | 0.924 to 3.490 | 0.084 |
| Acinar predominant | 0.446 | 0.228 to 0.875 | 0.019 | 0.461 | 0.216 to 0.986 | 0.046 |
| Papillary predominant | 1.161 | 0.624 to 2.160 | 0.637 | |||
| Micropapillary predominant | 2.789 | 1.532 to 5.077 | 0.001 | 1.115 | 0.560 to 2.221 | 0.757 |
| Solid predominant | 1.725 | 0.808 to 3.684 | 0.159 | |||
| Adjuvant therapy | 4.350 | 2.338 to 8.093 | < 0.001 | 1.667 | 0.760 to 3.655 | 0.202 |
| Brain metastasis-free survival | ||||||
| Age* | 0.993 | 0.970 to 1.015 | 0.520 | 0.996 | 0.971 to 1.022 | 0.783 |
| Female | 1.085 | 0.649 to 1.816 | 0.755 | 1.035 | 0.582 to 1.841 | 0.907 |
| Tumor size† | 1.498 | 1.304 to 1.721 | < 0.001 | 1.176 | 0.974 to 1.420 | 0.092 |
| N2 (vs. N0 or N1) | 3.701 | 2.138 to 6.408 | < 0.001 | 1.485 | 0.725 to 3.043 | 0.280 |
| Stage II or III (vs. stage I) | 4.823 | 2.865 to 8.121 | < 0.001 | 1.795 | 0.803 to 4.009 | 0.154 |
| Visceral pleural invasion | 1.892 | 1.051 to 3.407 | 0.034 | 1.177 | 0.620 to 2.235 | 0.618 |
| Angiolymphatic invasion | 4.679 | 2.759 to 7.934 | < 0.001 | 2.632 | 1.420 to 4.879 | 0.002 |
| Acinar predominant | 0.758 | 0.442 to 1.301 | 0.315 | |||
| Papillary predominant | 0.617 | 0.320 to 1.189 | 0.149 | |||
| Micropapillary predominant | 3.021 | 1.729 to 5.279 | < 0.001 | 2.186 | 1.148 to 4.163 | 0.017 |
| Solid predominant | 2.032 | 1.029 to 4.013 | 0.041 | 1.939 | 0.863 to 4.356 | 0.109 |
| Adjuvant therapy | 2.540 | 1.511 to 4.270 | < 0.001 | 0.698 | 0.345 to 1.410 | 0.316 |
| Bone metastasis-free survival | ||||||
| Age* | 1.000 | 0.977 to 1.023 | 0.990 | 0.992 | 0.968 to 1.018 | 0.556 |
| Female | 0.598 | 0.355 to 1.007 | 0.053 | 0.571 | 0.329 to 0.990 | 0.046 |
| Tumor size† | 1.593 | 1.408 to 1.802 | < 0.001 | 1.268 | 1.071 to 1.501 | 0.006 |
| N2 (vs. N0 or N1) | 4.694 | 2.774 to 7.942 | < 0.001 | 1.497 | 0.754 to 2.973 | 0.249 |
| Stage II or III (vs. stage I) | 5.431 | 3.211 to 9.186 | < 0.001 | 1.696 | 0.770 to 3.733 | 0.190 |
| Visceral pleural invasion | 2.644 | 1.404 to 4.977 | 0.003 | 1.497 | 0.758 to 2.954 | 0.245 |
| Angiolymphatic invasion | 5.791 | 3.397 to 9.874 | < 0.001 | 2.993 | 1.642 to 5.454 | < 0.001 |
| Acinar predominant | 0.661 | 0.380 to 1.149 | 0.143 | |||
| Papillary predominant | 0.761 | 0.411 to 1.407 | 0.383 | |||
| Micropapillary predominant | 2.048 | 1.139 to 3.683 | 0.017 | 1.324 | 0.683 to 2.567 | 0.406 |
| Solid predominant | 2.712 | 1.491 to 4.934 | 0.001 | 1.585 | 0.799 to 3.146 | 0.188 |
| Adjuvant therapy | 3.357 | 1.961 to 5.747 | < 0.001 | 1.072 | 0.541 to 2.124 | 0.843 |
| Liver metastasis-free survival | ||||||
| Age* | 0.994 | 0.950 to 1.040 | 0.803 | 0.983 | 0.935 to 1.035 | 0.518 |
| Female | 0.357 | 0.113 to 1.124 | 0.078 | 0.422 | 0.126 to 1.408 | 0.160 |
| Tumor size† | 1.601 | 1.234 to 2.077 | < 0.001 | 1.242 | 0.846 to 1.823 | 0.268 |
| N2 (vs. N0 or N1) | 5.027 | 1.784 to 14.169 | 0.002 | 2.986 | 0.625 to 14.263 | 0.170 |
| Stage II or III (vs. stage I) | 4.130 | 1.458 to 11.697 | 0.008 | 0.576 | 0.093 to 3.551 | 0.552 |
| Visceral pleural invasion | 1.798 | 0.572 to 5.649 | 0.315 | |||
| Angiolymphatic invasion | 5.794 | 1.975 to 16.996 | 0.001 | 3.699 | 1.117 to 12.246 | 0.032 |
| Acinar predominant | 0.577 | 0.183 to 1.817 | 0.348 | |||
| Papillary predominant | 0.418 | 0.094 to 1.855 | 0.251 | |||
| Micropapillary predominant | 0.943 | 0.211 to 4.212 | 0.939 | |||
| Solid predominant | 7.390 | 2.676 to 20.407 | < 0.001 | 4.093 | 1.340 to 12.504 | 0.013 |
| Adjuvant therapy | 3.289 | 1.122 to 9.647 | 0.030 | 1.556 | 0.412 to 5.872 | 0.514 |
HR, Hazard ratio; CI, confidence interval.
*
The HR associated with age is that the increase in hazard is associated with a 1-year increase in age.
†
The HR associated with tumor size is associated with a 1-cm increase in size.